Philippines

The Food and Drug Administration of the Philippines (FDA Philippines), operating under the Department of Health (DOH), is the primary regulatory authority for health products including pharmaceuticals, medical devices, diagnostics, and digital health solutions. Its mandate is governed principally by Republic Act No. 9711, known as the FDA Act of 2009, which modernized and strengthened the agency's powers over product registration, licensing, and post-market surveillance. All health products must secure a Certificate of Product Registration (CPR) or, for medical devices and diagnostics, a Marketing Authorization before they may be lawfully distributed in the country. The general approval process involves submission of a dossier to the appropriate FDA Center, a technical evaluation phase, and issuance of the authorization upon satisfactory review. FDA Philippines has adopted a risk-classification framework for medical devices aligned with ASEAN Medical Device Directive (AMDD) principles, and applies a Center for Drug Regulation and Research (CDRR) pathway for pharmaceuticals.

Applicants must appoint a locally registered company or a licensed importer/distributor as the Local Responsible Person (LRP), who assumes regulatory accountability in the Philippines. Dossier submissions are expected to follow the ASEAN Common Technical Dossier (ACTD) format for pharmaceuticals, while medical device submissions align with ASEAN CSDT requirements. FDA Philippines participates in the ASEAN harmonization initiatives and accepts data from recognized reference agencies such as the US FDA, EMA, TGA Australia, and Health Canada, which may qualify products for an expedited or abridged review pathway. In recent years, the agency has pursued significant reforms including the transition to an Electronic Registration System (eReg PH), implementation of a risk-based classification system for devices and diagnostics, and issuance of guidelines on digital health and software as a medical device (SaMD). Fees, timelines, and procedural requirements vary materially by product risk class and registration pathway.

Public procurement of health products in the Philippines is primarily administered through the Department of Health (DOH) at the national level, with the Philippine Health Insurance Corporation (PhilHealth) playing a central role in reimbursement policy. The DOH conducts centralized procurement through the Procurement Service of the Department of Budget and Management (PS-DBM) for priority medicines and health commodities, governed by Republic Act No. 9184, the Government Procurement Reform Act, and its Implementing Rules and Regulations. National procurement is typically executed via competitive public bidding, with awards published through the Philippine Government Electronic Procurement System (PhilGEPS). Regional health offices, government hospitals, and local government units (LGUs) may also conduct their own procurement within devolved structures introduced under the Local Government Code, creating a layered procurement landscape that requires engagement at both national and subnational levels. The National Formulary (PNF) and PhilHealth's Formulary Executive Council (FEC) benefit package listings serve as critical gatekeeping instruments, as inclusion substantially improves access to public sector volume.

The private sector represents a substantial share of total health expenditure in the Philippines, with products accessed through private hospital purchasing committees, retail pharmacy chains, and distributor networks. Multinational and local distributors play a pivotal role in both public and private channel penetration. The Philippines is also a recipient country for donor-funded health programs: the Global Fund supports HIV, tuberculosis, and malaria commodity procurement; USAID channels funding through its Medicines, Technologies, and Pharmaceutical Services (MTaPS) and other implementing partners; and UNICEF supports immunization supply chain and essential medicines access. Gavi, the Vaccine Alliance, also supports vaccine procurement for eligible programs. Regarding local manufacturing preference, the Philippine government has expressed policy intent to strengthen domestic pharmaceutical and health product manufacturing, including through the Philippine Pharmaceutical Industry Roadmap and executive directives encouraging local sourcing; however, formal mandatory local content requirements in procurement remain limited, and international suppliers remain competitive under open bidding frameworks.